Moderna Inc. (MRNA) has entered into an agreement with Spain’s Laboratorios Farmacéuticos Rovi, S.A. for large-scale manufacturing and supply of its mRNA-based experimental COVID-19 vaccine candidate outside of the U.S.Following the news shares rose 5.5% to $64.97 at the close on Thursday. As part of the agreement, Rovi will procure a new product line to provide vial filling and packaging, equipment for compounding, automatic visual inspection and labeling for the production of hundreds of millions of doses of the vaccine candidate to supply markets outside of the U.S. starting in early 2021, the two companies said in a statement.Rovi will …read more
Source:: Yahoo Finance
